Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (15)

Dec 2, 2040method-of-use (U-3928)US 11963962
Dec 2, 2040method-of-use (U-3928)US 11963962
Dec 2, 2040method-of-use (U-3928)US 11963962
Aug 21, 2039method-of-use (U-4441)US 12576089
Aug 21, 2039method-of-use (U-4441)US 12576089
Aug 21, 2039method-of-use (U-4441)US 12576089
Jun 11, 2035method-of-use (U-1201)US 9809559
Jun 11, 2035method-of-use (U-1201)US 9809559
Jun 11, 2035method-of-use (U-1201)US 9809559
Jun 11, 2035compositionUS RE48285
Jun 11, 2035compositionUS RE48285
Jun 11, 2035compositionUS RE48285
Jan 3, 2030compositionUS 84869413.4y
Jan 3, 2030compositionUS 84869413.4y
Jan 3, 2030compositionUS 84869413.4y

FDA exclusivities (6)

Sep 15, 2030ODE-441Orphan Drug (7y)4.1y
Sep 15, 2030ODE-441Orphan Drug (7y)4.1y
Sep 15, 2030ODE-441Orphan Drug (7y)4.1y
Sep 15, 2028NCENew Chemical Entity (5y)2.1y
Sep 15, 2028NCENew Chemical Entity (5y)2.1y
Sep 15, 2028NCENew Chemical Entity (5y)2.1y

News(2)

Five Under 5: Top Oncology Videos for the Week of 5/3
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.
onclive · 3mo ago
Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis
Andrew Kuykendall, MD, explains considerations for JAK inhibitor sequencing and the use of transplant in myelofibrosis.
onclive · 3mo ago

Data sources

openFDA · ClinicalTrials.gov

last refreshed 17m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

momelotinib dihydrochloride

Marketedupdated 3mo ago

by GlaxoSmithKline LLC

Approved

community read0 votes

🐶 often sniffed alongside

top 3

all catalysts(4)

approval · 4

Sep 15, 2023

approval

3y ago

OJJAARA (MOMELOTINIB DIHYDROCHLORIDE) — FDA approval

momelotinib dihydrochloride

OJJAARA (MOMELOTINIB DIHYDROCHLORIDE) — FDA approval

momelotinib dihydrochloride

OJJAARA (MOMELOTINIB DIHYDROCHLORIDE) — FDA approval

momelotinib dihydrochloride

OJJAARA (MOMELOTINIB DIHYDROCHLORIDE) — FDA approval

momelotinib dihydrochloride

→

Patent cliff

source: FDA Orange Book

first barrier falls

Sep 15, 2028

~2.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (15)

Dec 2, 2040method-of-use (U-3928)US 11963962
Dec 2, 2040method-of-use (U-3928)US 11963962
Dec 2, 2040method-of-use (U-3928)US 11963962
Aug 21, 2039method-of-use (U-4441)US 12576089
Aug 21, 2039method-of-use (U-4441)US 12576089
Aug 21, 2039method-of-use (U-4441)US 12576089
Jun 11, 2035method-of-use (U-1201)US 9809559
Jun 11, 2035method-of-use (U-1201)US 9809559
Jun 11, 2035method-of-use (U-1201)US 9809559
Jun 11, 2035compositionUS RE48285
Jun 11, 2035compositionUS RE48285
Jun 11, 2035compositionUS RE48285
Jan 3, 2030compositionUS 84869413.4y
Jan 3, 2030compositionUS 84869413.4y
Jan 3, 2030compositionUS 84869413.4y

FDA exclusivities (6)

Sep 15, 2030ODE-441Orphan Drug (7y)4.1y
Sep 15, 2030ODE-441Orphan Drug (7y)4.1y
Sep 15, 2030ODE-441Orphan Drug (7y)4.1y
Sep 15, 2028NCENew Chemical Entity (5y)2.1y
Sep 15, 2028NCENew Chemical Entity (5y)2.1y
Sep 15, 2028NCENew Chemical Entity (5y)2.1y

News(2)

Five Under 5: Top Oncology Videos for the Week of 5/3
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.
onclive · 3mo ago
Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis
Andrew Kuykendall, MD, explains considerations for JAK inhibitor sequencing and the use of transplant in myelofibrosis.
onclive · 3mo ago

Data sources

openFDA · ClinicalTrials.gov

last refreshed 17m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

momelotinib dihydrochloride

🐶 often sniffed alongside

all catalysts(4)

Patent cliff

patents (15)

FDA exclusivities (6)

News(2)

Report a data issue

comments(0)

momelotinib dihydrochloride

🐶 often sniffed alongside

all catalysts(4)

Patent cliff

patents (15)

FDA exclusivities (6)

News(2)

Report a data issue

comments(0)